Simulations Plus マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
Shawn O'Connor
最高経営責任者
US$1.1m
報酬総額
| CEO給与比率 | 47.85% |
| CEO在任期間 | 1.3yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 1.3yrs |
| 取締役会の平均在任期間 | 5.2yrs |
経営陣の近況
Recent updates
ナラティブの更新 • Apr 29
SLP: AI Regulatory Collaborations And Modest Growth Outlook Will Shape Balanced Future
Analysts have maintained their $16.00 price target for Simulations Plus, noting that slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E broadly offset one another in their updated models. What's in the News Announced a funded research collaboration with Lonza Group and the U.S. Food and Drug Administration (FDA) to develop a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, with the aim of supporting model informed drug development and potentially reducing reliance on some clinical bioequivalence studies (Key Developments).Seeking Alpha • Apr 12
Simulations Plus: Down Substantially, Not An Automatic Buy
Summary Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidance down. Valuation has compressed to 2.5x sales and ~20x realistic earnings, supported by a $42M net cash position. Despite improved margins and lower multiples, lack of growth and AI uncertainty keep me cautious on Simulations Plus. Read the full article on Seeking Alphaナラティブの更新 • Apr 12
SLP: AI Collaborations With Pharma And Regulators Will Drive Long-Term Upside
Analysts have reduced their price target for Simulations Plus from $20 to $16, citing updated assumptions that combine lower revenue growth expectations with a higher projected profit margin and a meaningfully lower future P/E multiple. What's in the News Simulations Plus announced collaboration programs with three large pharmaceutical companies to apply artificial intelligence within modeling workflows across the drug development lifecycle, using platforms such as GastroPlus, MonolixSuite, ADMET Predictor, and Thales (Key Developments).分析記事 • Feb 08
Simulations Plus, Inc.'s (NASDAQ:SLP) 26% Share Price Plunge Could Signal Some Risk
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Feb 06
Is There An Opportunity With Simulations Plus, Inc.'s (NASDAQ:SLP) 38% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$22.72 Simulations...
ナラティブの更新 • Jan 07
SLP: Reaffirmed Guidance And AI Roadmap Will Support Further Upside
Analysts have trimmed their price target on Simulations Plus to about US$22.33 per share, reflecting a slightly higher discount rate and P/E assumptions that point to a more cautious stance on profitability. What's in the News Simulations Plus plans an Analyst and Investor Day focused on presenting its new product vision and AI solutions, highlighting where management is aiming future product development (Key Developments).ナラティブの更新 • Dec 14
SLP: Reinforced Revenue Outlook Will Drive Upside From Current Levels
Analysts have modestly reduced their price target on Simulations Plus to approximately 22.33 dollars from 23 dollars. This reflects a recalibration of valuation multiples, even as they acknowledge stronger revenue growth and a significantly improved profit margin outlook.ナラティブの更新 • Nov 29
SLP: Revenue Guidance Will Support Renewed Upside Despite Index Exclusions
Analysts have maintained their price target for Simulations Plus at $23.00. They cited stable assumptions for revenue growth, profit margins, and valuation multiples in their latest assessment.ナラティブの更新 • Nov 15
SLP: Revenue Forecasts Will Drive Potential Gains Despite Index Removals
Analysts have modestly adjusted their price target for Simulations Plus from $23.00 to $23.00. They cite subtle changes in assumptions around discount rate and profit margins, while maintaining steady core growth expectations.ナラティブの更新 • Nov 01
SLP: Upcoming Earnings Guidance And Index Changes Will Drive Renewed Optimism
Analysts have adjusted their price target for Simulations Plus to $23.00. This reflects slight updates in their financial forecasts and expectations for future growth and profitability.分析記事 • Oct 28
Simulations Plus, Inc. (NASDAQ:SLP) Shares Could Be 44% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Simulations Plus fair value estimate is US$32.42 Simulations...ナラティブの更新 • Oct 18
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have maintained the fair value estimate for Simulations Plus at $23.00. This reflects stable long-term growth expectations, even with only slight adjustments to underlying assumptions.ナラティブの更新 • Oct 03
Software Licensing Expansion And Integrated Services Will Ensure Future Success
Analysts have revised their price target for Simulations Plus downward from $25.33 to $23.00, citing lower projected revenue growth and profit margins as key factors in their updated outlook. What's in the News Simulations Plus was removed from the S&P Composite 1500, S&P 1000, S&P 600, and S&P 600 Health Care indices (Key Developments).分析記事 • Jul 31
Some Simulations Plus, Inc. (NASDAQ:SLP) Shareholders Look For Exit As Shares Take 25% Pounding
Unfortunately for some shareholders, the Simulations Plus, Inc. ( NASDAQ:SLP ) share price has dived 25% in the last...分析記事 • Jun 13
Simulations Plus, Inc.'s (NASDAQ:SLP) Stock Retreats 36% But Earnings Haven't Escaped The Attention Of Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shares have had a horrible month, losing 36% after a relatively good period...分析記事 • May 07
Are Investors Undervaluing Simulations Plus, Inc. (NASDAQ:SLP) By 28%?
Key Insights The projected fair value for Simulations Plus is US$40.15 based on 2 Stage Free Cash Flow to Equity...Seeking Alpha • Apr 16
Simulations Plus: Benefiting From FDA Modernization And AI
Summary Simulations Plus, Inc. offers AI-based software tools for drug discovery and optimization, significantly reducing R&D time and costs for pharmaceutical research. SLP's diverse software portfolio, including GastroPlus and ADMET Predictor, and consulting services position it as a comprehensive partner in biotech development. Favorable regulatory changes by the FDA towards AI and non-animal testing methods boost SLP's market potential, despite its current high valuation. SLP's long-term outlook remains strong due to its innovative approach and the growing adoption of AI in drug testing, making it a "Buy" for long-term investors. Read the full article on Seeking Alpha分析記事 • Apr 13
Simulations Plus, Inc.'s (NASDAQ:SLP) 25% Jump Shows Its Popularity With Investors
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...分析記事 • Feb 08
Why Investors Shouldn't Be Surprised By Simulations Plus, Inc.'s (NASDAQ:SLP) 29% Share Price Surge
Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders would be excited to see that the share price has had a great month...分析記事 • Jan 08
Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...分析記事 • Nov 07
We Think Simulations Plus' (NASDAQ:SLP) Healthy Earnings Might Be Conservative
Despite posting healthy earnings, Simulations Plus, Inc.'s ( NASDAQ:SLP ) stock has been quite weak. Along with the...
新しいナラティブ • Oct 27
Biosimulation Innovations And Tactical Acquisitions To Boost Drug Development Growth
Integration and expansion into new markets drive revenue growth and improved profitability through increased efficiencies and enhanced offerings.Seeking Alpha • Aug 22
Simulations Plus: Declining Margins Are A Problem
Summary Simulations Plus growth is steady, but its margins continue to decline. This has been problematic due to the company's high valuation. Simulations Plus has suggested that the demand environment is improving, but its guidance implies a meaningful deceleration in organic growth. Simulations Plus likely needs to maintain its growth rate while improving margins before its share price moves higher. The decision to cut the company's dividend suggests that an improvement in margins and cash flows could be some way off. Read the full article on Seeking AlphaSeeking Alpha • Jul 10
Simulations Plus: Steady Growth, But What About The Margins?
Summary Simulations Plus, Inc. has seen stagnant stock trading despite impressive growth in the biosimulation market. Recent margin pressure and M&A activity raise concerns about management's ability to deliver. Acquisition of Pro-ficiency Holdings doubles the addressable market, but uncertainty remains about growth and margins amidst a demanding valuation. Read the full article on Seeking AlphaSeeking Alpha • May 14
Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts
Summary Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and underpenetrated, providing SLP with both organic and inorganic growth opportunities. While the company is operating in an attractive market and has a strong business, the company's valuation and growth prospects make the stock unappealing. Read the full article on Seeking AlphaCEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Feb 28 2026 | n/a | n/a | -US$63m |
| Nov 30 2025 | n/a | n/a | -US$64m |
| Aug 31 2025 | US$1m | US$525k | -US$65m |
| May 31 2025 | n/a | n/a | -US$63m |
| Feb 28 2025 | n/a | n/a | US$7m |
| Nov 30 2024 | n/a | n/a | US$8m |
| Aug 31 2024 | US$2m | US$512k | US$10m |
| May 31 2024 | n/a | n/a | US$10m |
| Feb 29 2024 | n/a | n/a | US$11m |
| Nov 30 2023 | n/a | n/a | US$11m |
| Aug 31 2023 | US$2m | US$487k | US$10m |
| May 31 2023 | n/a | n/a | US$10m |
| Feb 28 2023 | n/a | n/a | US$10m |
| Nov 30 2022 | n/a | n/a | US$11m |
| Aug 31 2022 | US$1m | US$450k | US$12m |
| May 31 2022 | n/a | n/a | US$12m |
| Feb 28 2022 | n/a | n/a | US$12m |
| Nov 30 2021 | n/a | n/a | US$10m |
| Aug 31 2021 | US$1m | US$444k | US$10m |
| May 31 2021 | n/a | n/a | US$12m |
| Feb 28 2021 | n/a | n/a | US$11m |
| Nov 30 2020 | n/a | n/a | US$10m |
| Aug 31 2020 | US$739k | US$350k | US$9m |
| May 31 2020 | n/a | n/a | US$9m |
| Feb 29 2020 | n/a | n/a | US$9m |
| Nov 30 2019 | n/a | n/a | US$9m |
| Aug 31 2019 | US$425k | US$325k | US$9m |
報酬と市場: Shawnの 総報酬 ($USD 1.10M ) は、 US市場 ($USD 1.72M ) の同様の規模の企業の平均を下回っています。
報酬と収益: Shawnの報酬は、過去 1 年間の会社の業績と一致しています。
CEO
Shawn O'Connor (65 yo)
1.3yrs
在職期間
US$1,096,572
報酬
Mr. Shawn M. O'Connor serves as Chief Executive Officer of Simulations Plus, Inc. since 2025 and had been Chief Executive Officer since June 26, 2018 until 2025. Mr. O'Connor joined Simulations Plus, Inc....
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chief Executive Officer | 1.3yrs | US$1.10m | データなし | |
| CFO, Executive VP & Corporate Secretary | 5.4yrs | US$534.65k | 0.010% $ 30.4k | |
| Chief Operating Officer | 1yr | US$358.27k | データなし | |
| Chief Revenue Officer | 1yr | US$488.97k | 0.44% $ 1.3m | |
| President of Services Solutions | no data | US$465.08k | 0.39% $ 1.1m | |
| Global Head of Strategic Alliances | 1yr | US$482.28k | 0% $ 0 | |
| Accounting Manager | no data | データなし | データなし | |
| Chief Science Officer | 5.7yrs | データなし | データなし | |
| VP of Corporate Counsel & Personal Data Protection Officer | no data | データなし | データなし | |
| Senior Director of Corporate Marketing | no data | データなし | データなし | |
| Vice President of Human Resources | 4.3yrs | データなし | データなし | |
| Chief Science Officer of Quantitative Systems Pharmacology | 1.3yrs | データなし | データなし |
1.3yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: SLPの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Director | 29.9yrs | US$155.27k | 16.17% $ 47.3m | |
| Independent Chairman of the Board | 9yrs | US$193.52k | 0.082% $ 239.4k | |
| Member of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Chairman of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Independent Director | 11.4yrs | US$180.02k | 0.072% $ 211.1k | |
| Member of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 5.2yrs | データなし | データなし | |
| Independent Director | 4.4yrs | US$175.52k | 0.085% $ 248.5k |
5.2yrs
平均在職期間
67.5yo
平均年齢
経験豊富なボード: SLPの 取締役会 は 経験豊富 であると考えられます ( 5.2年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 07:11 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/02/28 |
| 年間収益 | 2025/08/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Simulations Plus, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11
| アナリスト | 機関 |
|---|---|
| David Larsen | BTIG |
| Dane Leone | CGS International |
| Constantine Davides | Citizens JMP Securities, LLC |